BR112022012203A2 - Anticorpos para receptor alfa da interleucina-4 canino - Google Patents

Anticorpos para receptor alfa da interleucina-4 canino

Info

Publication number
BR112022012203A2
BR112022012203A2 BR112022012203A BR112022012203A BR112022012203A2 BR 112022012203 A2 BR112022012203 A2 BR 112022012203A2 BR 112022012203 A BR112022012203 A BR 112022012203A BR 112022012203 A BR112022012203 A BR 112022012203A BR 112022012203 A2 BR112022012203 A2 BR 112022012203A2
Authority
BR
Brazil
Prior art keywords
canine
receptor alpha
antibodies
alpha antibodies
canine interleukin
Prior art date
Application number
BR112022012203A
Other languages
English (en)
Inventor
Morsey Mohamad
Zhang Yuanzheng
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112022012203A2 publication Critical patent/BR112022012203A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICORPOS PARA RECEPTOR ALFA DA INTERLEUCINA-4 CANINO. A presente invenção fornece anticorpos para receptor alfa de IL-4 canino que têm uma alta afinidade de ligação para receptor alfa de IL-4 canino, e que podem bloquear a ligação da IL-4 e/ou IL-13 canina ao receptor alfa de IL-4 canino. A presente invenção está adicionalmente relacionada a epítopos de receptor alfa de IL-4 canino que se ligam aos anticorpos para o receptor alfa de IL-4 canino. A presente invenção fornece adicionalmente o uso dos anticorpos para o tratamento de dermatite atópica em cães.
BR112022012203A 2019-12-20 2020-12-18 Anticorpos para receptor alfa da interleucina-4 canino BR112022012203A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962951778P 2019-12-20 2019-12-20
US201962951793P 2019-12-20 2019-12-20
US202063015209P 2020-04-24 2020-04-24
US202063015220P 2020-04-24 2020-04-24
PCT/EP2020/086919 WO2021123089A1 (en) 2019-12-20 2020-12-18 Antibodies to canine interleukin-4 receptor alpha

Publications (1)

Publication Number Publication Date
BR112022012203A2 true BR112022012203A2 (pt) 2022-09-13

Family

ID=74183109

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022011797A BR112022011797A2 (pt) 2019-12-20 2020-12-18 Anticorpos contra receptor alfa de interleucina-4 canino
BR112022012203A BR112022012203A2 (pt) 2019-12-20 2020-12-18 Anticorpos para receptor alfa da interleucina-4 canino

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022011797A BR112022011797A2 (pt) 2019-12-20 2020-12-18 Anticorpos contra receptor alfa de interleucina-4 canino

Country Status (9)

Country Link
US (2) US20230053131A1 (pt)
EP (2) EP4077390A1 (pt)
JP (2) JP2023506924A (pt)
CN (2) CN114867526A (pt)
AU (2) AU2020409583A1 (pt)
BR (2) BR112022011797A2 (pt)
CA (2) CA3160589A1 (pt)
MX (2) MX2022007677A (pt)
WO (2) WO2021123089A1 (pt)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7208579B2 (en) 2003-05-30 2007-04-24 The Regents Of The University Of California IL4 receptor antagonists for horse, dog and cat
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CA3154540A1 (en) 2013-12-20 2015-06-25 Intervet International B.V. CANINIZED ANTIBODIES
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2017102920A1 (en) * 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Also Published As

Publication number Publication date
CA3162031A1 (en) 2021-06-24
AU2020407853A1 (en) 2022-06-09
JP2023506923A (ja) 2023-02-20
MX2022007677A (es) 2022-07-19
WO2021123091A1 (en) 2021-06-24
MX2022007672A (es) 2022-07-19
EP4077390A1 (en) 2022-10-26
US20230044037A1 (en) 2023-02-09
AU2020409583A1 (en) 2022-06-09
JP2023506924A (ja) 2023-02-20
EP4076653A1 (en) 2022-10-26
WO2021123089A1 (en) 2021-06-24
US20230053131A1 (en) 2023-02-16
CA3160589A1 (en) 2021-06-24
BR112022011797A2 (pt) 2022-08-30
CN114929746A (zh) 2022-08-19
CN114867526A (zh) 2022-08-05

Similar Documents

Publication Publication Date Title
BR112017020915A2 (pt) ?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune?
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
EA201792451A1 (ru) Антитела к ox40 и способы их применения
BR112015022123A8 (pt) Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112018067458A2 (pt) anticorpos para tigit
BR112018010891A2 (pt) anticorpos e fragmentos de anticorpos para a conjugação específica do sítio
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
MX2017010412A (es) Terapeuticos de anticuerpos que se unen a ctla4.
IN2014DN08011A (pt)
EA201692458A1 (ru) Анти-gitr антитела и способы их применения
BR112013021562A2 (pt) anticorpos para cd70
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
UA98983C2 (uk) Антитіло проти гепсидину та його застосування
GB2597851B (en) Antibody molecules that bind to NKP30 and uses thereof
BR112013032871A2 (pt) cepa hospedeira bacteriana que expressa dsbc recombinante
BR112022011629A2 (pt) Anticorpos biespecíficos caninizados para tratar dermatite atópica
BR112012010266A2 (pt) anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo